Compound structures and results of cytotoxicity testing for small molecules in Fig 2; specificity testing for toremifene and fluoxetine pseudotyped influenza H5N1 and vesicular stomatitis virus (VSV) (S1 Table).

All compounds tested in Fig 2 had cytotoxicity values higher than the IC₅₀ for the compounds pseudotyped WT-EBOV, WT-MARV, and EBOV mutants Y517S proving these compounds inhibit viral entry. (A) Structures of compounds tested in Fig 2; all compounds that bind to the EBOV/MARV GP have a positive charge at physiological pH (terminal amine); CA-074 and Leupeptin are peptide analogs and structurally distinct from the GP binders. (B) Toremifene showed no inhibition of pseudotyped vesicular stomatitis virus (VSV) proving its specificity to filovirus entry inhibition. (C) Fluoxetine showed no inhibition of pseudotyped vesicular stomatitis virus and influenza H5N1 proving its specificity to filovirus entry inhibition.

(TIF)